PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
FDA Approves New Treatment for HSDD in Premenopausal Women

FDA Approves New Treatment for HSDD in Premenopausal Women

by PEPID Newsroom | Jun 21, 2019 | Alerts

FDA approves bremelanotide  (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...

Recent Posts

  • Sepsis in the Emergency Department: Recognition and the First Hours
  • Opioid Use Disorder in the Emergency Department: Buprenorphine Initiation, Naloxone Distribution, and the Warm Handoff on International Overdose Awareness Day
  • Dementia in the Emergency Department: Recognizing Delirium, Anticholinergic Burden, and the “Acting Different” Presentation
  • Heat-Related Illness in the Emergency Department: Recognition, Cooling, and the High-Risk Patient
  • EMS Week in Practice: Strengthening the Prehospital-to-ED Continuum for Better Patient Outcomes

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved